Education
About Us
Working with TipRanks
Follow Us
Scopus BioPharma (SCPS)
OTHER OTC:SCPS
SCPS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.03 - $0.05
Previous CloseN/A
Volume4.28K
Average Volume (3M)2.18K
Market Cap
$12.63K
Enterprise Value$1.94M
Total Cash (Recent Filing)$362.10K
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta-90.84
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding42,084,263
10 Day Avg. Volume2,184
30 Day Avg. Volume2,184
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-0.31
Price to Sales (P/S)0.00
P/FCF Ratio-0.25
Enterprise Value/Market Cap153.87
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.04
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
―
Mutual Funds
<0.01% Other Institutional Investors
100.00% Public Companies and
Individual Investors
SCPS FAQ
What was Scopus BioPharma’s price range in the past 12 months?
Scopus BioPharma lowest stock price was $0.03 and its highest was $0.05 in the past 12 months.
What is Scopus BioPharma’s market cap?
Scopus BioPharma’s market cap is $12.63K.
When is Scopus BioPharma’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Scopus BioPharma’s earnings last quarter?
Currently, no data Available
Is Scopus BioPharma overvalued?
According to Wall Street analysts Scopus BioPharma’s price is currently Overvalued.
Does Scopus BioPharma pay dividends?
Scopus BioPharma does not currently pay dividends.
What is Scopus BioPharma’s EPS estimate?
Scopus BioPharma’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Scopus BioPharma have?
Scopus BioPharma has 42,084,263 shares outstanding.
What happened to Scopus BioPharma’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Scopus BioPharma?
Currently, no hedge funds are holding shares in SCPS
Company Description
Scopus BioPharma
Scopus BioPharma Inc., a clinical-stage biopharmaceutical company, focuses on developing transformational therapeutics targeting serious diseases. The company lead development programs are immuno-oncology gene therapy for the treatment of various cancers. It offers Duet Platform, a CpG signal transducer and activator of transcription 3 (STAT3) inhibitors; and MRI-1867, rationally designed, orally available, dual-action, hybrid, and small molecule that is an inverse agonist of the endocannabinoid system/cannabinoid receptor 1, as well as an inhibitor of inducible nitric oxide synthase. Scopus BioPharma Inc. has strategic partnerships with the City of Hope, National Institutes of Health Program, and The Hebrew University of Jerusalem for its lead development and other programs. The company was formerly known as Project18 Inc. and changed its name to Scopus BioPharma Inc. in December 2017. Scopus BioPharma Inc. was incorporated in 2017 and is headquartered in New York, New York.
Biodexa Pharmaceuticals
―
Salarius Pharmaceuticals
―
Processa Pharmaceuticals
―
GRI Bio
―
Onconetix
―